First Time Loading...
R

Rekah Pharmaceutical Industry Ltd
TASE:REKA

Watchlist Manager
Rekah Pharmaceutical Industry Ltd
TASE:REKA
Watchlist
Price: 1 297 ILS 5.02% Market Closed
Updated: Jun 2, 2024
Section:
 

Wall Street
Price Targets

REKA Price Targets Summary
Rekah Pharmaceutical Industry Ltd

There are no price targets for REKA.
REKA Lowest Forecast
Wall Street Target
Not Available
REKA Average Forecast
Wall Street Target
Not Available
REKA Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Rekah Pharmaceutical Industry Ltd Competitors:
Price Targets
ORCHPHARMA
Orchid Pharma Ltd
27% Upside
300255
Hebei Changshan Biochemical Pharmaceutical Co Ltd
13% Downside
PFE
Pfizer Inc
12% Upside
001630
Chongkundang Holdings Corp
26% Upside
ORCHPHARMA
Orchid Pharma Ltd
27% Upside
300255
Hebei Changshan Biochemical Pharmaceutical Co Ltd
13% Downside
PFE
Pfizer Inc
12% Upside
001630
Chongkundang Holdings Corp
26% Upside
T
300119
Tianjin Ringpu Bio-Technology Co Ltd
42% Upside
OCUL
Ocular Therapeutix Inc
159% Upside
H
293480
Hana Pharm Co Ltd
57% Upside
PFIZER
Pfizer Ltd
5% Upside

Revenue
Forecast

Revenue Estimate
Rekah Pharmaceutical Industry Ltd

Revenue forecast
is not available for
Rekah Pharmaceutical Industry Ltd

Operating Income
Forecast

Operating Income Estimate
Rekah Pharmaceutical Industry Ltd

Operating Income forecast
is not available for
Rekah Pharmaceutical Industry Ltd

Net Income
Forecast

Net Income Estimate
Rekah Pharmaceutical Industry Ltd

Net Income forecast
is not available for
Rekah Pharmaceutical Industry Ltd

See Also

Summary
REKA intrinsic value, competitors valuation, and company profile.
DCF Valuation
REKA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
REKA stock valuation using valuation multiples.
Wall Street Estimates
REKA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
REKA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is REKA's stock price target?
Not Available

REKA doesn't have any price targets made by Wall Street professionals.

ALPHA SPREAD
Join more than 142,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.